Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04093388 · ClinicalTrials.gov registry record · NA
Self-Collection of the Pap Smear as Agency: A Novel Way to Improve Refractory Low Cervical Cancer Screening Rates in Rural Alabama
A NA study of Cervical Cancer, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- NA
- Development phase
- 250
- Enrollment target
- 3
- Study locations
NCT04093388: Recruiting NA study of Cervical Cancer, sponsored by University of Alabama at Birmingham.
NCT04093388 is a NA study of Cervical Cancer that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 250 participants, below the 569-participant average among 144 other Cervical Cancer trials with a reported enrollment target (56% lower). The trial reports 3 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04093388, a NA study of Cervical Cancer, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- NA
- Development phase
- 250 participants
- Enrollment target
- 3
- Study locations
Study Summary
The purpose of the study is to find out if a self-administered (by the patient) Papanicolaou (Pap) smear is as accurate as a traditional Pap smear administered by a healthcare provider.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Self-PAP
- DIAGNOSTIC_TEST Traditional Pap smear
Study Locations (3)
Alabama
- Cahaba Medical Care - West End - Birmingham
- Cahaba Medical Care - Ensley - Birmingham
- Cahaba Medical Care - Centreville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2021-04-26 |
| Est. Completion | 2026-06-30 |
| Phase | NA |
What NCT04093388 shows while recruiting
NCT04093388 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, below the 569-participant average among 144 other Cervical Cancer trials with a reported enrollment target (56% lower).
The record links to 1 condition, with Cervical Cancer appearing as the primary indexed condition, and to 2 interventions - of which Self-PAP is the first listed.
NCT04093388 reports a single indexed study location in Alabama.
Frequently Asked Questions
What is clinical trial NCT04093388 about?
NCT04093388 is a clinical study titled "Self-Collection of the Pap Smear as Agency: A Novel Way to Improve Refractory Low Cervical Cancer Screening Rates in Rural Alabama". The purpose of the study is to find out if a self-administered (by the patient) Papanicolaou (Pap) smear is as accurate as a traditional Pap smear administered by a healthcare provider.
What is the current status of trial NCT04093388?
This trial is currently recruiting. It is a NA study. The enrollment target is 250 participants. The study started on 2021-04-26. Estimated completion is 2026-06-30.
What conditions does trial NCT04093388 study?
This clinical trial studies the following conditions: Cervical Cancer.
What interventions are being tested in trial NCT04093388?
The interventions under investigation include: Self-PAP (DIAGNOSTIC_TEST), Traditional Pap smear (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04093388?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04093388 being conducted?
This trial has 3 study locations across Alabama. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cervical Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04093388's enrollment target sits among peer trials
250 44th of 144 higher than 101 of 144 other Cervical Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cervical Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PopSci CHW4CervixHealth
RECRUITING · NA
-
ASk Questions in GYnecologic Oncology (ASQ-GYO)
RECRUITING · NA
-
ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
-
Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)
RECRUITING · NA
-
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI